ArticlePLoS neglected tropical diseases2018
Burden of leishmaniasis in Brazil and federated units, 1990-2016: Findings from Global Burden of Disease Study 2016.
Article in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Flavonoids in the treatment ofFrontiers in pharmacology · 2025Pooled it
- Diagnostic accuracy of serological rk-39 test for visceral Leishmaniasis: Systematic review and meta-analysis.PLoS neglected tropical diseases · 2024Pooled it
- The impact of leishmaniasis on mental health and psychosocial well-being: A systematic review.PloS one · 2019Pooled it
- Sand fly synthetic sex-aggregation pheromone co-located with insecticide reduces the incidence of infection in the canine reservoir of visceral leishmaniasis: A stratified cluster randomised trial.PLoS neglected tropical diseases · 2019Trial
- Insecticide-impregnated dog collars reduce infantile clinical visceral leishmaniasis under operational conditions in NW Iran: A community-wide cluster randomised trial.PLoS neglected tropical diseases · 2019Trial
- Pyridyl-Thiazole-Thiosemicarbazones as Antitrypanosomatidae Agents: Design, Synthesis, and In Silico Profiling.ChemMedChem · 2026Article
- [A spatiotemporal analysis of canine visceral leishmaniasis in Uruguaiana, Rio Grande do Sul, Brazil (2009-2019)].Cadernos de saude publica · 2026Article
- Article
- Global burden of leishmaniasis, 1990-2021: systematic analysis of the global burden of disease study.International journal for equity in health · 2025Article
- Spatiotemporal analysis of environmental factors associated with visceral leishmaniasis in northeastern Brazil, 2007-2022.Scientific reports · 2025Article
- Co-endemicity of schistosomiasis and tegumentary leishmaniasis: Spatial co-clustering in endemic areas.Tropical medicine & international health : TM & IH · 2025Article
- Global, regional, and national burden of Visceral leishmaniasis, 1990-2021: findings from the global burden of disease study 2021.Parasites & vectors · 2025Article
- Advances in Cysteine Protease B Inhibitors for Leishmaniasis Treatment.Current drug targets · 2025Review
- Epidemiologic aspects and spatial distribution of human visceral leishmaniasis: a cross-sectional study, Crateús, 2007-2023.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2025Article
- Spatial epidemiologic trends of cutaneous leishmaniasis in Rio de Janeiro State, Southeast Brazil, 2001-2020.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
- Spatial Analysis and Socio-Environmental Determinants of Canine Visceral Leishmaniasis in an Urban Area in Northeastern Brazil.Tropical medicine and infectious disease · 2024Article
- Spatial and temporal modeling of the global burden of Cutaneous Leishmaniasis in Brazil: A 21-year ecological study.PLoS neglected tropical diseases · 2024Article
- Clinical pattern and treatment outcome of cutaneous leishmaniasis patients in Somali region, eastern Ethiopia.Skin health and disease · 2024Article
- "It's not all about the disease": do treatment and socioeconomic status affect perceived impact and satisfaction of patients treated for cutaneous leishmaniasis?Revista da Sociedade Brasileira de Medicina Tropical · 2023Article
- Epidemiological and clinical characteristics of cutaneous leishmaniasis among patients attending at Tefera Hailu Memorial Hospital, Sekota, Northeast Ethiopia: A five-year trend analysis (2016-2020).SAGE open medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe study presents estimates for the burden of visceral leishmaniasis (VL) and cutaneous and mucocutaneous leishmaniasis (CML) in Brazil and its 27 federated units using data from the Global Burden of Disease Study (GBD) 2016. METHODOLOGY: We report the incidence, years of life lost (YLL), years lived with disability (YLD), and disability-adjusted life years (DALY) for leishmaniasis in Brazil from 1990 to 2016. The metrics are presented as age-standardized rates per 100,000 inhabitants with their respective uncertainty intervals (95%UI) and relative percentages of change. PRINCIPAL
findingsThe age-standardized incidence rate of leishmaniasis decreased 48.5% from 1990 (71.0, 95%UI 24.3-150.7) to 2016 (36.5, 95%UI 24.7-50.9), whereas the age-standardized DALY increased 83.6% over the studied period from 12.2 (95%UI 7.9-18.8) to 22.4 (95%UI 13.3-36.2). The age-standardized incidence rate and YLL for VL increased by 52.9% and 108% from 1990 to 2016, respectively. Considering CML, the age-standardized incidence rate and YLD decreased by 51% and 31.8% respectively for the same period. For VL, similar profiles for male and female were observed, with YLL and DALY increasing over time; with males presenting slightly higher values. The highest YLL rates were among "under 1-year old" children, which increased 131.2% from 1990 to 2016. Regarding CML, the highest values of YLD and DALY were verified among males, and YLD values showed a similar profile, with rates increasing with age. The VL burden increased in some states in the Northeast and Southeast regions and decreased for CML in some Northern states.
conclusionThe increase of VL burden over the study period might be associated with the difficulties in controlling the disease spread. Information regarding the weight of VL and CML, including the death and disability tolls that they cause, highlights the impact of these neglected diseases on public health and the importance of effective prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.